In this article
Third Avenue puts a small monthly medication price beside a much larger annual membership charge. For a reader checking whether the offer is credible, the first useful step is to separate those charges and identify which organization supplies medical care. A low headline price cannot answer either question on its own.
We checked Third Avenue’s public product pages, terms, refund policy and shipping policy on October 15, 2026. This is document research; we did not enroll, inspect a personalized checkout, verify individual licenses or test a prescription. CoreAge Rx is this publication’s featured commercial partner, disclosed in the placement below.
Third Avenue identifies a platform operator and medical group, but its advertised medication prices exclude a $199 annual membership after a seven-day trial. Its refund policy makes initial orders final at prescription issuance, while other pages describe later stages. Get the applicable terms in writing before paying.
What to know first
- Compounded semaglutide is advertised at $49/month and tirzepatide at $68/month, plus the separate membership.
- The terms name Third Ave LLC as the platform operator and MDI Medical Group PC and applicable affiliates as the medical group.
- Initial prescriptions and refills have different cancellation cutoffs in the refund policy; shipment is not the only relevant event.
A named company is the beginning of the check
The August 21, 2026 terms describe Third Ave LLC, a Delaware company, as a nonclinical technology and administrative business. Medical services are assigned to MDI Medical Group PC and applicable affiliated professional entities. Independent pharmacies dispense prescriptions; the terms do not guarantee a particular pharmacy for every order.
Those published identities provide something concrete to investigate. They do not establish the license status of the professional or pharmacy assigned to you. Request both names and check the relevant state records. Our online-pharmacy guide explains why the dispensing entity matters separately from the brand.
Read the medication bill and membership together
The semaglutide page advertises $49 per month and the tirzepatide page $68 per month, describing a flat medication price across doses. Both add a seven-day membership trial followed by $199 billed annually. The company says the membership covers care-team access, check-ins, member refill pricing and shipping.
A monthly-equivalent comparison should not conceal the annual charge. For illustration, twelve unchanged medication payments plus one $199 membership would total $787 for semaglutide or $1,015 for tirzepatide. That arithmetic is not a verified checkout quote, a required twelve-month medication purchase or a guarantee that the offer will remain available.
The pages say canceling during the trial avoids the membership charge. Save the trial start, billing date and cancellation confirmation. The terms describe cash-pay services, not insurance billing, and do not guarantee HSA/FSA reimbursement. The price-comparison guide helps record the whole commitment.
Payment comes before the prescribing decision
The refund policy says the displayed amount is charged before clinical review. If the provider declines treatment without issuing a prescription, it promises the treatment-request payment back. A materially different treatment or price requires affirmative acceptance; declining that alternative without a prescription also qualifies for the stated refund.
An unfinished intake is not automatically a cancellation. The policy permits a written cancellation while the request remains pending and before approval and prescription issuance. Ask separately what happens to the membership trial if clinical review is delayed or treatment is declined.
The public policies describe different stopping points
For an initial order requiring a new prescription, the refund policy makes the sale final when the clinician approves treatment and issues the prescription, even before pharmacy transmission. For refills under an existing prescription, it uses submission to, or acceptance for processing by, the pharmacy. It lists exceptions including inability to fulfill, compromised products and billing errors.
The shipping page instead describes finality after approval and pharmacy processing or shipment. It also permits a refund request if medication has not shipped within fourteen days of the order. These differences need written clarification; this review cannot decide which wording will govern an individual dispute.
The refund policy asks for damaged or incorrect products to be reported immediately, ordinarily within forty-eight hours of confirmed delivery. The homepage mentions seven days. Preserve the packaging and ask for instructions promptly rather than assuming the longer window applies. See our cancellation guide.
An overnight service is not overnight clinical review
The membership offer mentions overnight shipping. The shipping policy estimates pharmacy preparation and dispatch within one to two business days after approval and arrival for most orders within three to five business days of approval. These describe different stages. None is a delivery time measured by this publication.
The site describes messaging and continued clinical oversight. Ask how an urgent medication concern reaches the prescribing team, what follow-up is scheduled and how to obtain records if changing providers. Administrative availability is not a verified clinical response time.
The advertised product is compounded
The product pages explicitly describe compounded semaglutide and tirzepatide. FDA does not approve compounded drugs or review their safety, effectiveness and quality before marketing. Claims about lower-dose tolerability or longevity do not demonstrate those benefits for the exact formulation supplied through this program.
An assessment should identify the actual product, why it is proposed, the dispensing pharmacy and the individual follow-up plan. We did not authenticate the site’s star ratings or customer outcomes. The decision remains about a specific clinical and commercial arrangement, not a general “legit” badge.
Sources & research notes
Checked October 15, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- Third Avenue: Third AvenueProvider-published information · Checked October 15, 2026
- Third Avenue: Semaglutide | GLP-1 Metabolic SupportProvider-published information · Checked October 15, 2026
- Third Avenue: Tirzepatide | Metabolic Support CompoundProvider-published information · Checked October 15, 2026
- Third Avenue: Terms of serviceProvider-published information · Checked October 15, 2026
- Third Avenue: Refund policyProvider-published information · Checked October 15, 2026
- Third Avenue: Shipping policyProvider-published information · Checked October 15, 2026
- FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked October 15, 2026
- FDA BeSafeRx: checking online pharmaciesRegulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction